CD22 CAR for Non-Hodgkin's Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Stanford Medical Center, Stanford, CANon-Hodgkin's Lymphoma+3 MoreCD22 CAR - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a new immunotherapy treatment, using a patient's own immune cells, can be successful in treating adults with leukemia or lymphoma that has returned or does not respond to treatment.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Follicular Lymphoma, Grade 3b

Treatment Effectiveness

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: 28 days after infusion of CD22 CAR T cells

Day 28
T-Lymphocyte
Safe dose of CD22-CAR T cells in subjects with ALL
Month 28
Clinical activity of CD22-CAR T cells in adults with relapsed/refractory CD22-expressing B-cell ALL at target dose
Month 3
Clinical activity of CD22-CAR T cells in adults with relapsed/refractory aggressive B-cell NHL at MTD/RP2D
Day 11
Rate of successful manufacture of CD22 CAR T cells

Trial Safety

Trial Design

2 Treatment Groups

R/R ALL
1 of 2
R/R aggressive B-cell NHL
1 of 2

Experimental Treatment

92 Total Participants · 2 Treatment Groups

Primary Treatment: CD22 CAR · No Placebo Group · Phase 1

R/R ALLExperimental Group · 3 Interventions: CD22 CAR, Fludarabine, Cyclophosphamide · Intervention Types: Drug, Drug, Drug
R/R aggressive B-cell NHLExperimental Group · 3 Interventions: CD22 CAR, Fludarabine, Cyclophosphamide · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
FDA approved
Cyclophosphamide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days after infusion of cd22 car t cells

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,182 Previous Clinical Trials
35,091,841 Total Patients Enrolled
Lori Muffly, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
126 Total Patients Enrolled
Matthew Frank, MD, PhDPrincipal InvestigatorStanford University

Eligibility Criteria

Age 18+ · All Participants · 29 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your oxygen levels are above 92% without any extra help. You won't be excluded from the study if you have a certain level of low blood cell counts due to leukemia.
You can participate in the study even if you have brain involvement, as long as it doesn't affect the neurological tests used in the study.

Frequently Asked Questions

What is the primary purpose of administering CD22 CAR treatments?

"CAR-CD22 has been proven to work as an efficacious treatment for multiple sclerosis. Additionally, it is beneficial in managing cases of mixed-cell type lymphoma, leukemia, myelocytic and acute types of retinoblastoma." - Anonymous Online Contributor

Unverified Answer

What prior experiments have been conducted involving CD22 CAR technology?

"889 clinical trials relating to CD22 CAR are currently operational with 161 of these studies being conducted in phase 3. The majority of the research is concentrated around Philadelphia, Pennsylvania but there are 28443 sites worldwide conducting similar experiments." - Anonymous Online Contributor

Unverified Answer

Are there vacancies available to prospective participants of this clinical trial?

"According to clinicaltrials.gov, the research is in its recruitment stage. This trial was initially posted on September 12th 2019 and has been updated most recently on January 14th 2022." - Anonymous Online Contributor

Unverified Answer

How many individuals are currently participating in this research initiative?

"Affirmative. According to the clinicaltrials.gov database, this particular research is actively seeking participants; first posted on September 12th 2019 and last updated January 14th 2022. The study requires enrolment of 92 patients from a single medical centre." - Anonymous Online Contributor

Unverified Answer

Has the application for CD22 chimeric antigen receptor therapy been sanctioned by the Food and Drug Administration?

"Due to the experimental nature of this medical research, CD22 CAR has been rated a 1 on our safety scale. This is because Phase 1 trials provide limited evidence for efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.